These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

312 related articles for article (PubMed ID: 36629264)

  • 1. A novel consensus-based computational pipeline for screening of antibody therapeutics for efficacy against SARS-CoV-2 variants of concern including Omicron variant.
    Kumar N; Kaushik R; Zhang KYJ; Uversky VN; Sahu U; Sood R; Bhatia S
    Proteins; 2023 Jun; 91(6):798-806. PubMed ID: 36629264
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A Glycosylated RBD Protein Induces Enhanced Neutralizing Antibodies against Omicron and Other Variants with Improved Protection against SARS-CoV-2 Infection.
    Shi J; Zheng J; Tai W; Verma AK; Zhang X; Geng Q; Wang G; Guan X; Malisheni MM; Odle AE; Zhang W; Li F; Perlman S; Du L
    J Virol; 2022 Sep; 96(17):e0011822. PubMed ID: 35972290
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A Combination of Receptor-Binding Domain and N-Terminal Domain Neutralizing Antibodies Limits the Generation of SARS-CoV-2 Spike Neutralization-Escape Mutants.
    Haslwanter D; Dieterle ME; Wec AZ; O'Brien CM; Sakharkar M; Florez C; Tong K; Rappazzo CG; Lasso G; Vergnolle O; Wirchnianski AS; Bortz RH; Laudermilch E; Fels JM; Mengotto A; Malonis RJ; Georgiev GI; Quiroz JA; Wrapp D; Wang N; Dye KE; Barnhill J; Dye JM; McLellan JS; Daily JP; Lai JR; Herbert AS; Walker LM; Chandran K; Jangra RK
    mBio; 2021 Oct; 12(5):e0247321. PubMed ID: 34607456
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Epistasis at the SARS-CoV-2 Receptor-Binding Domain Interface and the Propitiously Boring Implications for Vaccine Escape.
    Rochman ND; Faure G; Wolf YI; Freddolino PL; Zhang F; Koonin EV
    mBio; 2022 Apr; 13(2):e0013522. PubMed ID: 35289643
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Biological Functions and Clinical Significance of SARS-CoV-2 Variants of Corcern.
    Akkız H
    Front Med (Lausanne); 2022; 9():849217. PubMed ID: 35669924
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Improved Binding Affinity of Omicron's Spike Protein for the Human Angiotensin-Converting Enzyme 2 Receptor Is the Key behind Its Increased Virulence.
    Kumar R; Murugan NA; Srivastava V
    Int J Mol Sci; 2022 Mar; 23(6):. PubMed ID: 35328828
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Correlation Analysis of Anti-SARS-CoV-2 RBD IgG and Neutralizing Antibody against SARS-CoV-2 Omicron Variants after Vaccination.
    Takheaw N; Liwsrisakun C; Chaiwong W; Laopajon W; Pata S; Inchai J; Duangjit P; Pothirat C; Bumroongkit C; Deesomchok A; Theerakittikul T; Limsukon A; Tajarernmuang P; Niyatiwatchanchai N; Trongtrakul K; Kasinrerk W
    Diagnostics (Basel); 2022 May; 12(6):. PubMed ID: 35741126
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Structural Study of SARS-CoV-2 Antibodies Identifies a Broad-Spectrum Antibody That Neutralizes the Omicron Variant by Disassembling the Spike Trimer.
    Zhan W; Tian X; Zhang X; Xing S; Song W; Liu Q; Hao A; Hu Y; Zhang M; Ying T; Chen Z; Lan F; Sun L
    J Virol; 2022 Aug; 96(16):e0048022. PubMed ID: 35924918
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Reduced Binding between Omicron B.1.1.529 and the Human ACE2 Receptor in a Surrogate Virus Neutralization Test for SARS-CoV-2.
    Hoffman T; Kolstad L; Akaberi D; Järhult JD; Rönnberg B; Lundkvist Å
    Viruses; 2023 May; 15(6):. PubMed ID: 37376580
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Epitope Classification and RBD Binding Properties of Neutralizing Antibodies Against SARS-CoV-2 Variants of Concern.
    Deshpande A; Harris BD; Martinez-Sobrido L; Kobie JJ; Walter MR
    Front Immunol; 2021; 12():691715. PubMed ID: 34149735
    [TBL] [Abstract][Full Text] [Related]  

  • 11. An RBD bispecific antibody effectively neutralizes a SARS-CoV-2 Omicron variant.
    Yuan M; Zhu Y; Liu G; Wang Y; Wang G; Zhang G; Ye L; Qian Z; Liu P
    One Health Adv; 2023; 1(1):12. PubMed ID: 37521533
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Identification of key mutations responsible for the enhancement of receptor-binding affinity and immune escape of SARS-CoV-2 Omicron variant.
    Wang WB; Ma YB; Lei ZH; Zhang XF; Li J; Li SS; Dong ZY; Liang Y; Li QM; Su JG
    J Mol Graph Model; 2023 Nov; 124():108540. PubMed ID: 37352723
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A Bifluorescent-Based Assay for the Identification of Neutralizing Antibodies against SARS-CoV-2 Variants of Concern
    Chiem K; Morales Vasquez D; Silvas JA; Park JG; Piepenbrink MS; Sourimant J; Lin MJ; Greninger AL; Plemper RK; Torrelles JB; Walter MR; de la Torre JC; Kobie JK; Ye C; Martinez-Sobrido L
    J Virol; 2021 Oct; 95(22):e0112621. PubMed ID: 34495697
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Omicron and Delta variant of SARS-CoV-2: A comparative computational study of spike protein.
    Kumar S; Thambiraja TS; Karuppanan K; Subramaniam G
    J Med Virol; 2022 Apr; 94(4):1641-1649. PubMed ID: 34914115
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In silico study of SARS-CoV-2 spike protein RBD and human ACE-2 affinity dynamics across variants and Omicron subvariants.
    Abeywardhana S; Premathilaka M; Bandaranayake U; Perera D; Peiris LDC
    J Med Virol; 2023 Jan; 95(1):e28406. PubMed ID: 36519577
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Computational prediction of the effect of amino acid changes on the binding affinity between SARS-CoV-2 spike RBD and human ACE2.
    Chen C; Boorla VS; Banerjee D; Chowdhury R; Cavener VS; Nissly RH; Gontu A; Boyle NR; Vandegrift K; Nair MS; Kuchipudi SV; Maranas CD
    Proc Natl Acad Sci U S A; 2021 Oct; 118(42):. PubMed ID: 34588290
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The structure of the RBD-E77 Fab complex reveals neutralization and immune escape of SARS-CoV-2.
    Zhang Z; Li X; Xue Y; Yang B; Jia Y; Liu S; Lu D
    Acta Crystallogr D Struct Biol; 2023 Aug; 79(Pt 8):746-757. PubMed ID: 37428848
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of human anti-spike protein receptor binding domain antibodies on severe acute respiratory syndrome coronavirus neutralization escape and fitness.
    Sui J; Deming M; Rockx B; Liddington RC; Zhu QK; Baric RS; Marasco WA
    J Virol; 2014 Dec; 88(23):13769-80. PubMed ID: 25231316
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Progress of the COVID-19: Persistence, Effectiveness, and Immune Escape of the Neutralizing Antibody in Convalescent Serum.
    Liang D; Zhang G; Huang M; Wang L; Hong W; Li A; Liang Y; Wang T; Lu J; Ou M; Ren Z; Lu H; Zheng R; Cai X; Pan X; Xia J; Ke C
    Pathogens; 2022 Dec; 11(12):. PubMed ID: 36558864
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Computational analysis of affinity dynamics between the variants of SARS-CoV-2 spike protein (RBD) and human ACE-2 receptor.
    Sultana N; Nagesha SN; Reddy CNL; Ramesh BN; Shyamalamma S; Shashidhara KS; Satish KM; Pradeep C; Vidyadhar GD
    Virol J; 2024 Apr; 21(1):88. PubMed ID: 38641844
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.